TrialCancer chemotherapy and pharmacology2022

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.

Jennifer E Hibma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.